$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000112534522000104 Filed on November 03, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$73.10M	$41.73M
YoY Change	416.71%	166.47%
Cost Of Revenue	$1.791M	$3.007M
YoY Change	89.12%	80.6%
Gross Profit	$71.31M	$38.73M
YoY Change	440.21%	176.68%
Gross Profit Margin	97.55%	92.79%
Selling, General & Admin	$13.67M	$15.36M
YoY Change	-12.26%	-10.52%
% of Gross Profit	19.17%	39.65%
Research & Development	$45.65M	$48.19M
YoY Change	-18.26%	-3.28%
% of Gross Profit	64.02%	124.44%
Depreciation & Amortization	$3.231M	$2.844M
YoY Change	9.45%	1.72%
% of Gross Profit	4.53%	7.34%
Operating Expenses	$59.33M	$48.19M
YoY Change	-16.95%	-3.28%
Operating Profit	$11.98M	-$24.96M
YoY Change	-120.58%	-52.9%
Interest Expense		$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$819.0K	$142.0K
YoY Change	282.71%	40.59%
Pretax Income	$12.80M	-$24.81M
YoY Change	-122.06%	-53.08%
Income Tax
% Of Pretax Income
Net Earnings	$12.80M	-$24.81M
YoY Change	-122.06%	-53.08%
Net Earnings / Revenue	17.51%	-59.46%
Basic Earnings Per Share		-$0.40
Diluted Earnings Per Share	$0.21	-$0.40
COMMON SHARES
Basic Shares Outstanding	61.48M shares	61.46M shares
Diluted Shares Outstanding		61.46M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$154.3M	$123.6M
YoY Change	-36.64%	-58.64%
Cash & Equivalents	$108.9M	$83.99M
Short-Term Investments	$45.46M	$39.62M
Other Short-Term Assets	$10.16M	$9.273M
YoY Change	-52.0%	-48.66%
Inventory	$1.451M	$1.086M
Prepaid Expenses	$10.16M
Receivables	$56.22M	$13.84M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$222.2M	$147.8M
YoY Change	-20.53%	-55.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$29.58M	$31.99M
YoY Change	-21.5%	-17.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.378M	$15.54M
YoY Change	-92.35%	-17.23%
Total Long-Term Assets	$58.29M	$47.54M
YoY Change	4.67%	-17.28%
TOTAL ASSETS
Total Short-Term Assets	$222.2M	$147.8M
Total Long-Term Assets	$58.29M	$47.54M
Total Assets	$280.5M	$195.3M
YoY Change	-16.34%	-50.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.899M	$4.619M
YoY Change	-68.39%	-25.14%
Accrued Expenses	$29.00M	$33.32M
YoY Change	-14.09%	-20.4%
Deferred Revenue	$9.988M	$7.085M
YoY Change	-51.62%	-56.57%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$48.61M	$50.05M
YoY Change	-34.82%	-27.33%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$258.0K	$258.0K
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$258.0K	$258.0K
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$48.61M	$50.05M
Total Long-Term Liabilities	$258.0K	$258.0K
Total Liabilities	$138.5M	$72.39M
YoY Change	44.79%	-28.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.094B	-$1.106B
YoY Change	12.3%	20.81%
Common Stock	$1.236B	$1.230B
YoY Change	1.82%	1.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$142.0M	$123.0M
YoY Change
Total Liabilities & Shareholders Equity	$280.5M	$195.3M
YoY Change	-16.34%	-50.19%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	$12.80M	-$24.81M
YoY Change	-122.06%	-53.08%
Depreciation, Depletion And Amortization	$3.231M	$2.844M
YoY Change	9.45%	1.72%
Cash From Operating Activities	$29.32M	-$9.422M
YoY Change	-153.99%	-36.32%
INVESTING ACTIVITIES
Capital Expenditures	$393.0K	-$804.0K
YoY Change	-128.58%	-62.31%
Acquisitions
YoY Change
Other Investing Activities	-$5.395M	$72.75M
YoY Change	-55.7%	-15130.99%
Cash From Investing Activities	-$5.788M	$71.95M
YoY Change	-57.29%	-2849.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.359M	0.000
YoY Change	69.88%	-100.0%
NET CHANGE
Cash From Operating Activities	29.32M	-9.422M
Cash From Investing Activities	-5.788M	71.95M
Cash From Financing Activities	1.359M	0.000
Net Change In Cash	24.89M	62.52M
YoY Change	-137.12%	3905.38%
FREE CASH FLOW
Cash From Operating Activities	$29.32M	-$9.422M
Capital Expenditures	$393.0K	-$804.0K
Free Cash Flow	$28.93M	-$8.618M
YoY Change	-154.65%	-31.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36112
	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1591613
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9704 Medical Center Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
	dei	City Area Code CityAreaCode	301
	dei	Local Phone Number LocalPhoneNumber	251-5172
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	MGNX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61475221	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83993000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	123469000	usd
CY2022Q3	us-gaap	Investments Investments	39623000	usd
CY2021Q4	us-gaap	Investments Investments	120147000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13837000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10386000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1086000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4388000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9273000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21170000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	147812000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	279560000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31993000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37676000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15542000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18009000	usd
CY2022Q3	us-gaap	Assets Assets	195347000	usd
CY2021Q4	us-gaap	Assets Assets	335245000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4619000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15500000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33321000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33755000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7085000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	20646000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5021000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4677000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	50046000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	74578000	usd
CY2022Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5084000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	17001000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	20791000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	72389000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	95627000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61462189	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61307428	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	615000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	613000	usd
CY2022Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1228952000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1213002000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-113000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-61000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1106496000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-973936000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	122958000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	239618000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	195347000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	335245000	usd
CY2022Q3	us-gaap	Revenues Revenues	41734000	usd
CY2021Q3	us-gaap	Revenues Revenues	15662000	usd
	us-gaap	Revenues Revenues	78842000	usd
	us-gaap	Revenues Revenues	63300000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3007000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1665000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3235000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1704000	usd
CY2022Q3	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	136000	usd
CY2021Q3	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	0	usd
	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	2358000	usd
	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	0	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48191000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49823000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	161373000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	158724000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15355000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17161000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	45277000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47431000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	66689000	usd
CY2021Q3	us-gaap	Costs And Expenses CostsAndExpenses	68649000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	212243000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	207859000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-24955000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-52987000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-133401000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-144559000	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	142000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	101000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	841000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	466000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-24813000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-52886000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-132560000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-144093000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	213000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-52000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24600000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52890000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-132612000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144089000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.86
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.86
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.42
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.42
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61459831	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61459831	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61169754	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61169754	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61390143	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	61390143	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59494836	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59494836	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	239618000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5224000	usd
CY2022Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	37000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-222000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-66443000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	178214000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5350000	usd
CY2022Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	264000	usd
CY2022Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-43000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-41304000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	142481000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5077000	usd
CY2022Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	0	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	213000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-24813000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	122958000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	295884000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5243000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	98200000	usd
CY2021Q1	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	2458000	usd
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	18000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-51272000	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	350531000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6113000	usd
CY2021Q2	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	2346000	usd
CY2021Q2	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-10000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-39935000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	319045000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6309000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	19640000	usd
CY2021Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	-666000	usd
CY2021Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-52886000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	291438000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-132560000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-144093000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8634000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8306000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-740000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1267000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	15697000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	17714000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2882000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1602000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3452000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9322000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-419000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5582000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11898000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1080000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2468000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-5146000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-10897000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-1931000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-184000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7744000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3447000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-2701000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-8477000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	14507000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	0	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	258000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-116279000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-89521000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	75457000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	164780000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	155190000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	146550000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3230000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4826000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	76503000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23056000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117818000	usd
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	314000	usd
	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	5722000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	14000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1563000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	300000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	121977000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39476000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9400000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123469000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181131000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83993000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	190531000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	295000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	69000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2000000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	39736000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	113000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	39623000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	120208000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4900000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	61000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	120147000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	209000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3929000	usd
CY2022Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	877000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	459000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	1086000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4388000	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	mgnx	Share Based Compensation Arrangement By Share Based Payment Award Offering Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod	P6M
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5123000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6358000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15697000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17714000	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8373921	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.47
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2730597	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.40
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	82963	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	427074	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.05
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	267238	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	22.76
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10327243	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.63
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	124000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6455853	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.77
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	96000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9622594	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	18.96
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y7M6D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	120000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.89
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.21
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	500000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3200000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	300000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5400000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	15100000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	14800000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	28600000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D

Files In Submission

Name	View Source	Status
0001125345-22-000104-index-headers.html	Edgar Link	pending
0001125345-22-000104-index.html	Edgar Link	pending
0001125345-22-000104.txt	Edgar Link	pending
0001125345-22-000104-xbrl.zip	Edgar Link	pending
exhibit101-incyte3rdamend.htm	Edgar Link	pending
exhibit31-1q32022.htm	Edgar Link	pending
exhibit31-2q32022.htm	Edgar Link	pending
exhibit32-1q32022.htm	Edgar Link	pending
exhibit32-2q32022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20220930.htm	Edgar Link	pending
mgnx-20220930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mgnx-20220930_cal.xml	Edgar Link	unprocessable
mgnx-20220930_def.xml	Edgar Link	unprocessable
mgnx-20220930_pre.xml	Edgar Link	unprocessable
mgnx-20220930_lab.xml	Edgar Link	unprocessable
mgnx-20220930_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2022 Q4 Form 10-Q Financial Statement

#000112534522000104 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2022 Q4 Form 10-Q Financial Statement

#000112534522000104 Filed on November 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx